HMG CoA 還元酵素阻害剤 (スタチン) と大動脈弁のカルシウム
David M Shavelle1, Junichuro Takasu, Matthew J Budoff
1Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA 98195-6422, USA.
Lancet (London, England)
|April 12, 2002
まとめ
スタチンは,大動脈弁のカルシウム (AVC) の蓄積の進行を遅らせる可能性がある. この研究では,スタチンの使用はAVCの蓄積率と進行を著しく低下させることを発見しました.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- 放射線学 放射線学
背景:
- Calcific aortic valvular sclerosis/stenosisは,薬理学的治療が欠けている. 薬理学的な治療は,薬理学的な治療が欠けている.
- 大動脈弁のカルシフィケーションは,脂質タンパク質の堆積と関連しています.
研究 の 目的:
- 3-ヒドロキシ-3-メチルグルタリル-共酵素A (HMG COA) 還元酵素阻害剤 (スタチン) が,大動脈弁のカルシウム (AVC) の蓄積を遅らせる可能性を調査する.
主な方法:
- 2つの電子ビームコンピュータトモグラフィースキャンを受けた65人の患者の遡及的分析.
- スタチンを服用している患者と服用していない患者のAVC蓄積率の比較.
主要な成果:
- スタチンを服用した患者はAVCの蓄積率の中央値が62%~63%低かった (p=0.006).
- スタチンを服用している患者の44~49%が,AVCの進行を明確に示した (p=0.043).
結論:
- スタチンは,AVCの蓄積を減らすための潜在的な治療戦略を表す可能性があります.
- カルシフ性大動脈弁疾患の管理におけるスタチンの有効性を確認するために,さらなる研究が必要である.
関連する概念動画
Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


